Aptar Pharma signs nose-to-brain drug delivery research pact with Massachusetts General Hospital
Aptar Pharma has entered a research collaboration with Massachusetts General Hospital, led by Alice Stanton, to build a predictive screening platform for nose-to-brain (N2B) drug delivery. The New Approach Methodology will combine in vitro, in vivo and computational tools to identify molecules suited to intranasal delivery for central nervous system disorders including Alzheimer's and Parkinson's disease. The tool is intended to incorporate Aptar's Cerespray and Neurospray nasal delivery platforms to guide formulation and device design for pharmaceutical partners.
Why this mattersA validated screening platform could shorten development timelines for CNS drugs and strengthen Aptar's positioning as a device partner earlier in pharma R&D.
- Research collaboration agreement signed with Massachusetts General Hospital, led by Alice Stanton, PhD
- Project targets a New Approach Methodology (NAM) for nose-to-brain (N2B) drug delivery screening
- Platform combines in vitro, in vivo and computational technologies to characterise transport mechanisms
- NAM is intended to incorporate Aptar's Cerespray and Neurospray nasal delivery platforms
- Target applications include Alzheimer's, Parkinson's, multiple sclerosis and depression
- Aptar cites 30 years of field data behind its proprietary nasal delivery systems
- Aptar named Daniel Ackerman interim Chief Accounting Officer while he continues as Senior Vice President, Finance for Aptar Pharma.